Antimalarial medication

The Cardiac Risk of Chloroquine in Unapproved Indications

Friday, March 27, 2020 - 1:57am

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.

March 26 Statement: Lupus Research Alliance Puts Plaquenil Shortage Into Perspective For Lupus Community

Thursday, March 26, 2020 - 1:07pm

Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.

Key Points: 
  • Thrust into the spotlight has been news about the potential benefit of anti-malarial drugs commonly used for lupus, hydroxychloroquine (brand name Plaquenil) and chloroquine, in treating COVID-19.
  • The Lupus Research Alliance will continue to monitor the situation closely and push for continued access for people with lupus while working to ensure shortages abate in the future.
  • More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.

The Quinism Foundation Calls on State Boards of Pharmacy to Enact Uniform Restrictions to Limit Hoarding of Quinoline Antimalarial Drugs Against COVID-19

Monday, March 23, 2020 - 11:00pm

WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.

Key Points: 
  • WHITE RIVER JUNCTION, Vt., March 23, 2020 /PRNewswire-PRWeb/ --The Quinism Foundation has called on state boards of pharmacy to enact uniform restrictions on the dispensing of the quinoline antimalarial drugs hydroxychloroquine, chloroquine, mefloquine, primaquine, tafenoquine, and quinine to limit hoarding in response to the COVID-19 pandemic.
  • [1,2] "However, the same common properties that likely underlie the effectiveness of these quinoline antimalarial drugs against the virus may also underlie their common dangers."
  • "While hydroxychloroquine is among the safest drugs of the quinoline antimalarial class, all antimalarial quinolines share a common toxicity," said Dr. Nevin.
  • Dr. Nevin also emphasized that the Quinism Foundation has recently called on Congress to fund research into chronic quinoline encephalopathy.

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

Friday, February 28, 2020 - 10:00pm

Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."

Key Points: 
  • Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
  • [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.
  • Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist.
  • The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.

Boragen Collaborates With Leading Universities to Extend the Benefits of Its Boron-based Platform Across Agriculture, Animal Health and Human Health

Tuesday, February 11, 2020 - 2:00pm

In fact, this is what excites our scientists the most: postulating potential applications and uncovering new mechanisms of action.

Key Points: 
  • In fact, this is what excites our scientists the most: postulating potential applications and uncovering new mechanisms of action.
  • Recent research data have shown that boron chemistry is a promising source of novel antimalarial drugs, said Dr. Philip Rosenthal, Professor, Dept.
  • Since one of the most widely-deployed fungicide classes are also used in medicine, resistance is a major global health threat.
  • The company utilizes borons unique properties to design and develop novel solutions targeting needs in crop protection, animal health and human health.

Arakoda™ (Tafenoquine) Tablets, First Prescription Drug Approved for Malaria Prevention by US FDA in Over 18 Years, Now Available in US

Thursday, November 21, 2019 - 1:01pm

This significant milestone complements the regulatory approval of Arakoda by the United States Food and Drug Administration (FDA).

Key Points: 
  • This significant milestone complements the regulatory approval of Arakoda by the United States Food and Drug Administration (FDA).
  • Arakoda (tafenoquine) is approved for the prevention of malaria in adults and was the first anti-malarial product approved for prevention in over 18 years.
  • Arakoda has the potential to protect thousands of U.S. travelers and military personnel from the devastating and life-threatening effects of malaria.
  • 60P continues to work closely with distribution networks and third-party insurance companies to provide extensive access to the product.

ExxonMobil Continues Support for Fight Against Malaria

Thursday, April 25, 2019 - 7:51pm

ExxonMobil said today that it is committing $5.7 million in support for local and global organizations working to eliminate malaria around the world.

Key Points: 
  • ExxonMobil said today that it is committing $5.7 million in support for local and global organizations working to eliminate malaria around the world.
  • While great progress continues to be made in saving lives from malaria around the world, important work remains to prevent the diseases resurgence.
  • ExxonMobil works with partners in Angola, Cameroon, Chad, Equatorial Guinea, Mozambique, Nigeria and Papua New Guinea to identify and promote solutions to fight the disease.
  • Chan School of Public Health, Jhpiego, Malaria No More, PATH Malaria Vaccine Initiative, Seed Global Health, Special Olympics, Tchova Tchova, ExxonMobil Global Health Scholars at the University of Oxford and Worldwide Antimalarial Resistance Network (WWARN).

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

Tuesday, April 23, 2019 - 7:00am

GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.

Key Points: 
  • GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.
  • VivAccess is set to accelerate their access to those in need and in doing so protect patients from relapses and support countries to move towards malaria elimination."
  • In the process, the initiative will strengthen national and local capacities in alignment with the WHO malaria strategic agenda .
  • "Relapsing malaria due to Plasmodium vivax is the most geographically widespread malaria, with well over 2 billion people living in areas of risk for infection, said Dr. Larry Slutsker , Director of the PATH Center for Malaria Control and Elimination.

PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria

Tuesday, April 23, 2019 - 7:00am

GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.

Key Points: 
  • GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.
  • VivAccess is set to accelerate their access to those in need and in doing so protect patients from relapses and support countries to move towards malaria elimination."
  • In the process, the initiative will strengthen national and local capacities in alignment with the WHO malaria strategic agenda .
  • "Relapsing malaria due to Plasmodium vivax is the most geographically widespread malaria, with well over 2 billion people living in areas of risk for infection, said Dr. Larry Slutsker , Director of the PATH Center for Malaria Control and Elimination.

$830 Bn Artemisinin Combination Market - Global Outlook & Forecast Report 2017-2026

Thursday, January 31, 2019 - 9:00pm

The "Artemisinin Combination - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artemisinin Combination - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Global Artemisinin Combination Therapy (ACT) market accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period.
  • Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market.
  • However, limited number of manufacturers globally acts as a hindrance for the market growth.